The specific interaction between CD18 and ICAM‐1 has been previously utilized to enhance the targeting efficacy of a nano‐delivery platform (AM@ZIF@NM) to plaque endothelial cells, effectively mitigating inflammation in atherosclerotic lesions and alleviating atherosclerosis.[20] This study utilizes targeted nanomedicine combined with ultrasound for rapid thrombolysis. The gene discussed is ICAM1; the disease is atherosclerosis.